Return to homepagePandemic Pact

Inhaled oligonucleotides to generate a decoy receptor for the SARS Coronarvirus-2

  • Funded by National Health and Medical Research Council (NHMRC)
  • Total publications:0 publications

Grant number: GA85472

Grant search

Key facts

  • Disease

    COVID-19

  • Start & end year

    2020
    2021

  • Known Financial Commitments (USD)

    $204,969.95

  • Funder

    National Health and Medical Research Council (NHMRC)

  • Research Location

    Australia

  • Lead Research Institution

    Monash University

  • Research Priority Alignment

    N/A

  • Research Category

    Therapeutics research, development and implementation

  • Research Subcategory

    Pre-clinical studies

  • Special Interest Tags

    Innovation

  • Study Type

    Non-Clinical

  • Clinical Trial Details

    Unspecified

  • Broad Policy Alignment

    Pending

  • Age Group

    Not Applicable

  • Vulnerable Population

    Not applicable

  • Occupations of Interest

    Not applicable

Abstract

The SARS-Coronavirus-2 gains access to the human body by binding to ACE2 on the surface of certain cells. We have found a practical way to change ACE2 so that it is no longer on the surface of cells, so can't be used as a conduit for virus entry. Moreover, by still being able to bind to the virus, this soluble ACE2 can act as a decoy receptor to prevent virus accessing other cells. This technology has been approved for use in humans, and represents a novel strategy for COVID-19.